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Microsatellite instability (MSI), the abnormal shortening or length-
ening of DNA by 1–6 repeating base pair units, is the result of 
inactivation of the DNA mismatch repair (MMR) system and 
characterizes approximately 15% of colorectal cancers (CRCs) (1). 
Two distinct mechanisms can cause MMR deficiency (dMMR): 1) 
germline mutational inactivation of the MMR genes, present in 
CRC patients with Lynch Syndrome and 2) epigenetic silencing by 
hypermethylation of CpG islands in the MMR gene promoters, 
present in the vast majority of sporadic MSI CRCs (2,3). It has long 
been recognized that MSI CRCs form a unique subset of CRC 
patients with different clinical behavior compared with patients 
with proficient DNA MMR (pMMR) cancers, whose tumors are 
characterized as microsatellite stable (MSS). A number of retro-
spective studies and a meta-analysis (4) have supported the favor-
able stage-adjusted prognosis of MSI CRC patients compared with 
MSS CRC patients. However, a putative predictive role of MSI for 
response to 5-fluorouracil (5-FU) adjuvant chemotherapy has been 
proven to be a contentious issue and was the topic of two recent 
articles (5,6) and a 2009 American Society of Clinical Oncology 
(ASCO) abstract (7). The article by Ribic et al. (5) found that 
untreated CRC patients with MSI tumors have a modestly better 
prognosis than those with MSS tumors, but did not seem to benefit 
from the 5-FU-based adjuvant chemotherapy. There was even a 
suggestion of harm in terms of overall survival (OS) in treated CRC 
patients with MSI tumors. These findings were confirmed 5 years 
later, when a pooled analysis was performed by Sargent et al. (6) 
that included 457 new CRC patients and the previously published 
570 CRC patients (5). Of the total 1027 patients analyzed, 515 
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untreated stage II and stage III CRC patients with MSI tumors 
showed a clearly improved rate of 5-year disease-free survival 
(DFS) compared with MSS tumors, whereas no such difference in 
5-year DFS rate was observed in the other 512 treated stage II and 
stage III patients (6), which suggested that the survival benefit of 
patients with MSI tumors was abrogated by 5-FU treatment. 
However, in more than 600 stage II and stage III patients under 
treatment with 5-FU in the control arm of the PETACC3 study 
(7), we observed a statistically significant difference in the rate of 
5-year DFS in patients with MSI tumors compared with MSS 
tumors (P = .0077) (7), suggesting that the improved prognosis in 
patients with MSI tumors was maintained under 5-FU treatment. 
Furthermore, we showed in another 2009 ASCO abstract (8) that 
the incidence of MSI differed between stage II and stage III colon 
cancer and the prognostic impact of MSI was substantially stronger 
in stage II colon cancer patients compared with stage III patients. 
These results suggested that prognosis should be stratified not only 
by treatment, but also by stage, if the current controversial data on 
prognosis are to be resolved. Patient series that are large enough to 
stratify per stage and randomized for treatment or no treatment are 
necessary to study prognostic vs predictive effects of MSI. 
Unfortunately, to date, the available datasets have not been suffi-
ciently informative to provide unambiguous answers.
In this issue of the Journal, Sinicrope et al. (9) present a new 
effort at getting sufficient samples from internationally diverse 
adjuvant clinical trials in which CRC patients were randomized 
between 5-FU and no treatment or no 5-FU treatment to further 
explore the impact of dMMR on clinical outcomes. They elabo-
rated the association of MMR status with CRC recurrence vari-
ables such as rate, time to recurrence (TTR), and site of recurrence 
(local, intra-abdominal, or distant), as well as with survival (DFS 
and OS). Furthermore, they examined the impact of 5-FU-based 
adjuvant chemotherapy on the above-mentioned recurrence vari-
ables in an attempt to provide further insights into the clinical 
behavior of MSI vs MSS CRC tumors that could be useful in 
patient management and clinical decision making.
In this study, Sinicrope et al. (9) included 1686 stage II and 
stage III CRC patients and their respective colorectal tissue speci-
mens in addition to the previously published series of 457 patients 
(6) for analysis of an impressive total of 2141 CRC patients and 
specimens. This was accomplished by the inclusion of eight more 
adjuvant trials (10–13) and by increasing the number of CRC 
patients and tissue specimens from some of the previously included 
trials (6). Nevertheless, in spite of the impressive number of 
patients studied, it should be stressed that only patients with 
available tissue specimens from the adjuvant therapy trials were 
included in the analysis, thus representing a subset of the overall 
study cohorts. Of the 2141 CRC patients, 344 patients had MSI 
tumors (164 stage II and 180 stage III tumors). Although the adju-
vant trials included in the analysis are rather old, run in several 
countries, have incomplete tissue availability, and some have com-
parative treatment groups, they have long periods of follow-up and 
meticulous data collection and reflect the international diverse 
adjuvant trial programs. Without any doubt, this is one of the 
strongest points of the current article (9).
The article (9) confirms the overall better prognosis of CRC 
patients harboring MSI tumors compared with MSS tumors, 
shown in previous studies (4–6). Indeed, more in line with what we 
have previously reported (7), treated and untreated patients with 
stage II and stage III MSI CRC tumors showed a statistically sig-
nificant improvement in TTR (P < .001), DFS, and OS (P = .004) 
compared with patients with MSS tumors. However, when the 
data were analyzed by tumor stage in a univariate analysis, the 
association of MSI to improved outcome, although similar for stage 
II and stage III patients (Pinteractions ≥ .641), remained statistically 
significant only in stage III patients (TTR, P = .016; DFS, P = .047; 
OS, P = .041).
Unfortunately, Sinicrope et al. (9) did not formally compare the 
predictive value of MSI status for DFS or OS in patients treated in 
the adjuvant 5-FU-based clinical trials compared with untreated 
control groups in the available cohorts. The rationale for that 
decision, according to the authors, is that such an analysis had been 
performed in a previous article (6), which included a subset of the 
current study (9) population. In the previous article, Sargent et al. 
(6) observed a statistically significant improved DFS (P = .001) in 
patients with stage III MSS tumors receiving adjuvant 5-FU che-
motherapy, but no treatment effect was observed in patients with 
stage III MSI tumors. A non-statistically significant benefit of 
adjuvant therapy was observed in patients with stage II MSS 
tumors, whereas a trend toward worse outcome was observed in 
patients with stage II MSI tumors (6). Given, the modest number 
of CRC patients with MSI tumors available for analysis, the 
authors were careful not to overstate the findings (6). Both accom-
panying editorials of this article (14,15) noted that the differences 
between MSS and MSI tumors and between stage II and stage III 
CRC patients were important and may have important implica-
tions for decisions on treatment, but the data produced did not 
justify exclusion of CRC patients with MSI tumors from the stan-
dard 5-FU-based adjuvant treatment. Although clinicians have 
been eager to implement this notion into clinical decision making, 
the results (6) were obviously in need of further validation by con-
firmation studies.
In the current article, Sinicrope et al. (9) report a benefit of 
5-FU treatment for stage III CRC patients with MSI tumors, con-
trary to what was previously reported (5,6). However, the authors 
added an important new variable and studied the impact of MSI of 
presumed sporadic vs germline (ie, Lynch Syndrome) origin on the 
outcome after 5-FU-based chemotherapy. The beneficial treat-
ment effect on TTR and DFS in stage III MSI CRC patients 
seemed to be restricted to tumors where MSI originated from 
a germline defect in one of the DNA MMR genes, whereas no 
benefit of 5-FU therapy was found in sporadic MSI tumors with an 
epigenetic origin. Unfortunately, no formal analysis of the treat-
ment effect in stage II CRC patients with MSI tumors was per-
formed. Furthermore, the article (9) did not provide any data on 
stage II MSI CRC patients, so the statistical significance of germ-
line vs sporadic MSI in stage II colon cancer is not clear. 
Intuitively, this distinction makes perfect sense because of the dif-
ferent molecular mechanisms underpinning the MSI status of 
germline vs sporadic MSI tumors, and thus, if validated, would 
constitute a further subdivision of the MSI colon cancer patients. It 
should, however, be pointed out that unorthodox criteria were used 
to distinguish presumed hereditary vs sporadic MSI carcinomas. 
The used criteria were dMMR phenotype (either from MSI testing or 
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from MMR protein expression analyzed by immunohistochemistry), 
age at adjuvant study randomization (cutoff of 55 years from the 
modified Amsterdam criteria for Lynch Syndrome) (16,17), and 
BRAF mutation status (as it occurs only in sporadic dMMR CRCs) 
(18), but molecular genetic analysis of germline DNA (16,17) was 
not performed. This approach carries important potential bias, and 
thus the approach and its outcome have to be considered explor-
atory for the time being. Furthermore, the article reports a 
number of disturbingly quick recurrences before 6 months (and 
not after 1 year) in the presumed germline MSI CRC untreated 
patients, as shown in Figure 3, A (9), indicating a particularly 
bad prognosis and driving the observation of large benefit of 5-FU 
in this population. The worse prognosis of untreated CRC patients 
with presumed germline MSI tumors is unexpected and needs to 
be validated. On the reverse side, if indeed only the CRC patients 
with presumed germline MSI tumors benefit from 5-FU therapy, 
then CRC patients with presumed sporadic MSI tumors could be 
resistant to 5-FU therapy, possibly because of MMR gene hyper-
methylation, and this would affect the treatment paradigms for 
10% of colon cancer patients. Furthermore, as noted by the 
authors (9), the possibility of a non–MMR-related mechanism 
being responsible for these findings cannot be excluded, which 
needs to be validated and confirmed.
This article (9) also demonstrates an association between the 
site of tumor recurrence, MMR status, and the outcome of adju-
vant chemotherapy for the first time, and shows that CRC patients 
with MSI tumors had overall lower rates of tumor recurrence com-
pared with MSS tumors, notably as regards recurrence at distant 
sites (P < .001). When analyzed by stage, the association between 
MMR status and site of recurrence was found in stage III and not 
in stage II patients. In addition, in patients with MSS stage III 
tumors, 5-FU-based adjuvant treatment vs observation (surgery 
alone) or no 5-FU therapy was associated with a lower number of 
distant recurrences for patients with MSI tumors (P = .01) and any 
recurrence (P < .001) (9).
This study (9) represents a valid opportunity to address the 
burning questions remaining after the study by Sargent et al. (6): 1) 
did lack of benefit of 5-FU therapy in stage III MSI CRC patients 
represent overtreatment and 2) was treatment of stage II MSI 
CRC patients with 5-FU harmful? Both issues have important 
clinical implications, and both tentative conclusions from the study 
by Sargent et al. (6) showing a lack of effect for stage III MSI CRC 
or harm for stage II MSI CRC patients could have represented 
spurious findings because of sample size (6), and urgently needed 
validation. In a multivariable analysis, Sinicrope et al. (9) showed 
MMR status to be a statistically significant independent prognostic 
variable in patients with MSI tumors, with an improved TTR (P = 
.005), DFS (P = .035), and OS (P = .031) compared with those with 
MSS tumors. However, despite analyzing a large number of new 
CRCs, the authors did not perform a stratified analysis of treat-
ment effect by treatment group or by stage.
In conclusion, the results of this article by Sinicrope et al. (9) 
provide valuable information about the prognostic and certainly 
the predictive role of dMMR, including the intriguing difference 
between germline vs sporadic origin of dMMR, highlighting 
that sometimes the mechanism responsible for an event reflects 
more than the event itself. This hypothesis-generating information 
in the current analysis needs to be validated in an independent 
dataset. It is important to consider whether these results are suffi-
cient to validate MMR assessment as a prerequisite for selecting 
CRC patients for adjuvant therapy.
From a practical point of view, on one hand, the data provided 
in this study (9) are important and reassuring to the clinicians 
because the lack of benefit of 5-FU therapy in stage III MSI 
tumors (5,6) could not be replicated. On the other hand, from an 
academic point of view, it is frustrating that even in studies with 
such large patient populations, questions such as the different 
impact of MSI status between stage II and stage III CRC patients 
and the potential harm in stage II CRC MSI patients after 5-FU 
treatment remain unanswered. Although hypothesis-generating 
data on the relationship between MMR status and relapse site, as 
well as data on the difference between germline and somatic MMR 
deficiencies are now available (9), the puzzle still has many missing 
pieces. In the future, other parameters, such as gene expression 
profiling, ploidy, methylation, and microRNA assessment, will 
probably have to be taken into account to robustly characterize 
clinically relevant biological subgroups. To get there, large datas-
ets will be needed for prognostic and predictive studies. We may 
not have banked enough tissue samples in the past to ever get the 
answers that we need. Hopefully, in recent trials such as PETACC8 
(19) and NCT00079274 (20–22), where the addition of cetuximab 
to the current standard adjuvant combination therapy of 5-FU, 
leucovorin, and oxaliplatin (FOLFOX) is elaborated in stage III 
CRC patients, the tissue banking performed will help us find the 
biological subgroups that will benefit from the standard and com-
bination chemotherapy regimens.
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